Showing 2623 results
- https://www.novartis.com/news/media-releases/novartis-renouvelle-son-engagement-afin-deliminer-le-paludisme-en-investissant-100-millions-de-dollars-dans-la-recherche-et-le-developpement-dantipaludiques-de-nouvelle-generationL'entreprise s'apprête à investir plus de 100 millions de dollars afin de faire progresser la recherche et le développement de nouveaux antipaludiques au cours des cinq prochaines années L'…
- https://www.novartis.com/news/media-releases/novartis-tender-offer-avexis-commencesBasel, April 17, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Novartis AM Merger Corporation, a Delaware corporation ("Purchaser"), has…
- https://www.novartis.com/news/media-releases/novartis-announces-new-analysis-demonstrating-entresto-helped-preserve-kidney-function-patients-chronic-heart-failure-especially-those-diabetesHeart failure (HF) patients with reduced ejection fraction treated with Entresto experienced significantly less reduction in kidney function compared to patients treated with standard of care ACE…
- https://www.novartis.com/news/media-releases/novartis-enters-agreement-acquire-avexis-inc-usd-87-bn-transform-care-sma-and-expand-position-gene-therapy-and-neuroscience-leaderAveXis lead product candidate, AVXS-101, has potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong…
- https://www.novartis.com/news/media-releases/novartis-schliesst-vereinbarung-zum-erwerb-von-avexis-inc-fur-usd-87-mrd-ab-um-therapie-der-sma-zu-transformieren-und-position-als-fuhrendes-gentherapie-und-neuroscience-unternehmen-auszubauenFührender Produktkandidat von AveXis, AVXS-101, hat das Potenzial, erste Genersatztherapie zur einmaligen Anwendung zur Behandlung der spinalen Muskelatrophie (SMA) zu werden eine…
- https://www.novartis.com/news/media-releases/sandoz-outlines-plans-next-healthcare-access-challenge-hack-support-local-digital-innovationSandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare Publication, which coincides with World…
- https://www.novartis.com/news/media-releases/novartis-announces-jama-cardiology-publication-data-showing-entresto-improves-physical-and-social-activity-hfref-patients-versus-enalaprilPost-hoc analysis of PARADIGM-HF published in JAMA Cardiology shows heart failure patients treated with Entresto experience significant improvements in physical and social activities compared to…
- https://www.novartis.com/news/media-releases/novartis-present-predictability-data-brolucizumab-namd-from-pivotal-hawk-and-harrier-trials-arvoBasel, March 28, 2018 - Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting,…
- https://www.novartis.com/news/media-releases/novartis-sell-stake-consumer-healthcare-joint-venture-gsk-usd130-billion-focus-strategic-prioritiesPrice reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best long-term…
- https://www.novartis.com/news/media-releases/novartis-verkauft-beteiligung-consumer-healthcare-joint-venture-fur-usd-13-milliarden-gsk-um-sich-auf-strategische-prioritaten-zu-konzentrierenPreis stellt für Novartis einen attraktiven Wert dar Verkaufserlös wird in Übereinstimmung mit den Prioritäten für die Kapitalallokation verwendet, einschliesslich für Bolt-on-Akquisitionen Verkauf…
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- …
- 263
- › Next page